According to J&J, the contact lens features proprietary Max technologies meant to to boost comfort and visual clarity, even at day 14. The company plans to roll out the product in select European countries later this year, with a wider market rollout in 2027.
“People who choose reusable contact lenses should not have to compromise on comfort or clarity as their days get busier and their eyes work harder,” said Jacqueline Henderson, company group chair of Vision at J&J MedTech. “With Acuvue Oasys Max 2-Week, we are bringing our most advanced Acuvue technologies to a reusable lens, helping more people see clearly and feel comfortable throughout the full two-week wear cycle.”
The news release out today from J&J is but some of the next extra news that has caught our eye over at MassDevice in recent days. Other recent medtech news came from CorTec, Getinge, and Applied BioCode. Stories included:
- CorTec received a second FDA Breakthrough Device Designation for its Brain Interchange system, now covering communication so that people with non-progressive quadriplegia — paralysis in all four limbs — can control a computer cursor through thought alone.
- Getinge on Sept. 8 announced the launch of Torin Plan Optimizer, an AI-powered decision support solution for surgical planning.Getinge today announced the launch of Torin Plan Optimizer, an AI-powered decision support solution for surgical planning.
- Applied BioCode inked a distribution agreement with Henry Schein that expands availability of its BioCode MDx-3000 system for hospitals and reference laboratories.
